Analysts Set Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Price Target at $33.33

Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) have been assigned a consensus recommendation of “Moderate Buy” from the eight research firms that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $33.3333.

CRVS has been the topic of several research analyst reports. Weiss Ratings upgraded Corvus Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 28th. Wall Street Zen downgraded Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. LADENBURG THALM/SH SH upgraded Corvus Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, July 30th. Finally, The Goldman Sachs Group started coverage on Corvus Pharmaceuticals in a research report on Friday, April 17th. They set a “buy” rating and a $40.00 price target on the stock.

Insider Transactions at Corvus Pharmaceuticals

In other news, Director David Scott Moore acquired 21,700 shares of the stock in a transaction that occurred on Thursday, June 11th. The shares were acquired at an average cost of $11.53 per share, for a total transaction of $250,201.00. Following the purchase, the director owned 21,700 shares of the company’s stock, valued at approximately $250,201. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 19.70% of the company’s stock.

Hedge Funds Weigh In On Corvus Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CRVS. Quarry LP bought a new stake in shares of Corvus Pharmaceuticals in the third quarter valued at approximately $27,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Corvus Pharmaceuticals by 26.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,629 shares of the company’s stock worth $28,000 after buying an additional 748 shares during the period. Global Retirement Partners LLC bought a new position in Corvus Pharmaceuticals in the 2nd quarter worth approximately $30,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in Corvus Pharmaceuticals in the 2nd quarter valued at approximately $48,000. Finally, Russell Investments Group Ltd. purchased a new position in Corvus Pharmaceuticals in the 3rd quarter valued at approximately $49,000. Institutional investors own 46.64% of the company’s stock.

Corvus Pharmaceuticals News Roundup

Here are the key news stories impacting Corvus Pharmaceuticals this week:

• Positive Sentiment: An independent analysis examines soquelitinib’s clinical science, commercial market opportunity and fair value, keeping attention focused on the potential upside from Corvus’s lead program. The stock has increased from its 52-week low, suggesting investors continue to assign meaningful value to the drug’s development prospects. Corvus: Evaluating Soquelitinib’s Science, Market Reach, And Fair Value
• Neutral Sentiment: HC Wainwright issued a new FY2030 earnings forecast for Corvus. The article does not provide the estimate, but the long-range projection indicates analysts are continuing to model the company’s path toward commercialization and profitability. FY2030 Earnings Forecast for CRVS Issued By HC Wainwright
• Negative Sentiment: HC Wainwright lowered EPS estimates across multiple periods: FY2026 to a loss of $0.83 from $0.66, FY2027 to a loss of $0.80 from $0.63, FY2028 to a loss of $0.37 from $0.25, and FY2029 to a loss of $0.01 from a profit of $0.07. Quarterly estimates were also reduced, including Q3 2026 to a loss of $0.23 from $0.17 and Q1–Q4 2027 to losses ranging from $0.16 to $0.24 per share. These revisions imply slower progress toward profitability and could pressure sentiment. HC Wainwright Earnings Estimate Revisions for Corvus Pharmaceuticals

Corvus Pharmaceuticals Stock Up 0.6%

CRVS opened at $15.14 on Friday. The stock has a market cap of $1.27 billion, a price-to-earnings ratio of -24.82 and a beta of 0.87. Corvus Pharmaceuticals has a twelve month low of $4.70 and a twelve month high of $26.95. The company’s 50-day moving average price is $13.64 and its two-hundred day moving average price is $15.14.

Corvus Pharmaceuticals (NASDAQ:CRVS) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.03). As a group, sell-side analysts anticipate that Corvus Pharmaceuticals will post -0.79 earnings per share for the current year.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company’s research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.

Corvus’s lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape.